Business Wire

SHIPPEO

22.5.2023 17:46:25 CEST | Business Wire | Press release

Share
Shippeo Recognized in the 2023 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms

Shippeo, a global leader in real-time multimodal transportation visibility, today announced it has been recognized in the Gartner® Magic Quadrant™ for Real-time Transportation Visibility Platforms.

“I am pleased to see many of Shippeo’s recognitions over the past 12 months reflected, we believe, in our positioning in this year’s Magic Quadrant,” says Shippeo co-founder and COO, Lucien Besse.

Shippeo has a 95% willingness to recommend rating on Gartner Peer Insights™, receiving the overall rating of 4.8/5*. “These are highly important metrics for us, and reassure us that we are providing our customers with the best value, and delivering what we promise,” says Besse, adding “we believe this high customer satisfaction was helped by the fact we are the only provider to offer a triple SLA, which contractually guarantees rapid carrier onboarding, high tracking rates, and high ETA accuracy, as well as the tremendous progress we have made across all aspects of our business over the last 12 months.”

The company recently raised a record $50m in fundraising, with all existing investors taking part. “This fundraising round is the largest ever for a supply chain visibility software in Europe,” explains Besse. “It will help us bolster our sound financial position for many years to come, and accelerate our ongoing North American and APAC expansion, while giving customers and partners confidence in the longevity potential of our partnerships with the strong path to profitability we’ve laid out as a company.”

Existing investors taking part included Battery Ventures, Partech, NGP Capital, ETF Partners, Bpifrance Digital Venture and SAP.io. Notable new strategic investors include Hong Kong-based LFX Venture Partners and Japan-based Yamaha Motor Ventures, whose investment is helping to ramp up operations across Asia-Pacific, as well as Orlen VC, based in Poland, and Shift4good, a global VC fund dedicated to impact investing in smart mobility and circular economy businesses.

An expert in sustainability, Shift4good strictly invests in companies with the potential to move the needle on climate change. Beyond a strong belief in the company’s business potential, Shift4Good’s decision to invest was driven by the potential of Shippeo’s new Carbon Visibility solution to have a positive impact across the transportation and logistics sector. The emissions calculator, now generally available to all customers, combines Shippeo’s advanced visibility data capabilities with cutting edge data modeling from industry expert Searoutes, to provide extremely accurate transport and distribution GHG (CO2e) emissions reporting. The tool offers users GLEC-accredited CO2 equivalent emissions calculations, without the need to manually consolidate data supplied by carriers.

Continued expansion into North America and APAC was boosted by a new global partnership with e2open, offering Shippeo’s native real-time in-transit visibility within their comprehensive global supply chain management platform.

The company also recently welcomed some of the most iconic brands in the world, including Amazon, Barilla (US), Epson, Geodis, Jacob Douwe Egberts (JDE), Jaguar Land Rover, Lassonde, L'Oréal, Moët Hennessy (LVMH), SABIC International (the second largest public company in the Middle East) and Siemens Energy.

Over the last year, Shippeo’s team grew to more than 230 Shippians, including senior executive and SaaS veteran Philippe Vanhove as new Chief Revenue Officer, who brings 25 years of experience in scaling fast-growing, international SaaS organizations, having managed multinational sales operations, marketing, lead generation, human resources, and finance.

In April, the company launched a new biannual platform release cycle, delivering its latest Spring platform release. New and enhanced features across all transport modes introduced to users improve the platform experience and enhance visibility data quality. Highlights include a new Shippeo berth ETA as part of their Ocean Visibility offering, which is significantly more accurate and reliable than the ones received from ocean carriers, as well as new vessel AIS-based milestone detection for more accurate milestones at ports during loading, unloading and transshipment. A swathe of usability enhancements throughout the multimodal visibility platform include new container delay filters, carrier TMS tag synchronization, and configurable notifications to help users manage shipments more efficiently, by exception.

2022 also saw the launch of Shippeo’s Carrier Recognition Program, celebrating over 400 of the world’s most exceptional carriers, who provide the best service to shippers with consistently high levels of shipment tracking. The company also held their inaugural Visibility Star Awards last November, which recognize the efforts our carrier community has made to provide great service to their clients, and celebrate their exceptional commitment to real-time visibility.

More information:

*Disclaimer:
* Gartner Disclaimer: based on 214 reviews as of May 18 2023 in the Real-Time Transportation Visibility Platforms market.

Gartner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2023” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 16 May 2023.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more collaborative, automated, sustainable, profitable, and customer-centric supply chains. This is made possible with highly accurate, real-time operational visibility and perfect workflow orchestration. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and accurately measure CO2 and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Siemens Energy, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 32 million shipments per year across 110 countries. Learn more at www.shippeo.com
LinkedIn, Facebook, Twitter

About Shift4Good
Shift4Good is a venture capital fund manager dedicated to impact investing in smart mobility & circular economy start-ups. With teams based in both Paris and Singapore, Shift4Good mostly focus on European and Southeast Asian opportunities. Shift4Good can deploy between €0.5m and €20m per company and mostly invest in Series A and Series B rounds and can allocate 10% of their funds to pre-Series A rounds. More information: https://www.shift4good.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005162/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye